非奈利酮联合标准方案治疗射血分数轻度降低型或保留型心力衰竭的药物经济学评价
2025-08-18夏茹楠王旭陈慧娟姜梦雨狄潘潘赵蒙蒙刘丽梁海
中图分类号R956 文献标志码A 文章编号 1001-0408(2025)14-1770-05
DOI 10.6039/j.issn.1001-0408.2025.14.14
ABSTRACTOBJECTIVEToevaluate thecost-efectivenessof finerenonecombinedwith standardofcare(SoC)inthe treatmentofheartfailurewithmildlyreducedejectionfraction(HFmrEF)orpreservedejectionfraction(HFpEF).METHODS BasedonaphaseIIclinical tial,a MarkovmodelwasconstructedfromtheperspectiveofChina’shealthcaresystemtocompare thetreatmentoutcomesoffinerenonecombinedwithSoCregimenversusSoCregimenaloneinthetreatmentofdiferentcardiac functionalstatusesofHFmrEF/HFpEF.Usingquality-adjustedlifeyear(QALY)asthehealthoutputindex,3times China’sper capita GDPin2023asthewilingnes-to-pay(WTP)threshold,asimulationwasconducted witha3-monthcyclelengthanda10- year time horizon,incorporating an annual discount rate of 5% .The dynamic changes across various stages of HFmrEF/HFpEF treatedwith finerenonecombinedwithSoCversusSoCaloneweresimulatedtoevaluatethelong-termefectivenessandcostsof the twotreatmentstrategies.Additionally,oe-waysensitivityanalysisndprobabilisticsnsitivityanalysswereperformed,totesthe robustnessof theresults.RESULTSTheicrementalcost-efectivenessratio(ICER)ofthefinerenonecombinedwith SoCregimen versusSoCregimenalonewas179504.75yuan/QALY,whichwas belowtheWTPthresholdset inthis study,indicating thatthe finerenonecombinedwith SoCregimenposessedcertaineconomicadvantages.Theresultsofone-waysensitivityanalysis showed thattheutiltyvalueofNYHAIstatus,thedrugpriceoffierenone,thediscountrate,andtheprobabilityofhospital tansfefor bothgroups hadagreat influenceonICER,butdidnotafect therobustessofthemodel.Theprobabilisticsensitivityanalysisalso confirmedtherobustnessof the model.CONCLUsIONS Under theWTPthresholdset inthis study,finerenonecombined with SoC is cost-effective in the treatment of HFmrEF/HFpEF,compared with the SoC regimen.
KEYWORDSfinerenone;HFmrEF;HFpEF;Markov model;cost-utility analysis
心力衰竭(heartfailure,HF)是各种心脏疾病的严重表现或晚期阶段,以呼吸困难、疲乏和液体潴留等为主要临床表现,具有较高的患病率和死亡率[1-2]。目前,全球HF患病人数约为3700万例3,我国HF患病人数约为890万例,其中射血分数轻度降低型心力衰竭(heartfailurewith mildly reduced ejection fraction,HFmrEF)或射血分数保留型心力衰竭(heart failurewith preservedejectionfraction,HFpEF)是主要的HF亚型。《中国心力衰竭诊断和治疗指南2024》对HF的标准治疗方案(thestandardofcare,SoC)进行了推荐,包括使用利尿剂、血管紧张素受体脑啡肽酶抑制剂(angiotensinreceptor-neprilysininhibitor,ARNI)、血管紧张素转换酶抑制剂(angiotensin converting enzyme inhibitor,ACEI)、血管紧张素受体阻滞剂(angiotensinreceptorblockers,ARB)和β受体阻滞剂等,但未对HFmrEF/HFpEF亚型的治疗方案给予明确的推荐药物。研究显示,盐皮质激素受体拮抗剂(mineralocorticoid receptor antagonist,MRA)可以有效降低射血分数降低的心力衰竭(heartfailurewithre-ducedejectionfraction,HFrEF)的患病率和死亡率,但其在改善HFmrEF/HFpEF患者预后方面的作用仍有待进一步研究。非奈利酮作为新型非甾体类MRA,对盐皮质激素受体具有较高的选择性和亲和力,能够防止盐皮质激素受体过度激活,从而减轻纤维化和炎症反应,具有肾脏和心血管保护作用。临床前研究显示,在HFpEF动物模型中,非奈利酮可减轻心脏舒张功能障碍并改善心脏灌注。一项全球多中心、随机、双盲的Ⅲ期临床试验(FINEARTS-HF研究)显示,非奈利酮联合SoC可以显著降低HFmrEF/HFpEF患者的心血管相关不良事件的发生风险[风险比为 0.82,95% 置信区间(confi-dence interval,CI)为 0.71~0.94,P=0.006] []。这一研究成果为这类患者的治疗提供了新的选择,进一步拓宽了其在HF治疗领域中的应用范围。
据统计,每年我国花费的与HF相关的直接和间接总成本约为54亿美元。……
